Abstract. Ikaros is a member of the Kruppel family of zinc finger DNA-binding proteins. The Ikaros protein contains two separate regions of zinc-finger domains: 4 DNA-binding zinc fingers near the N-terminus and 2 zinc fingers for proteinprotein interactions near the C-terminus. Here, we identified the Ikaros gene from 14 vertebrate genomes and found Ikaros existed in all kinds of vertebrate including fish, amphibians, birds and mammals. Moreover, except rat and Xenopus tropicalis Ikaros proteins, which lack the first C2H2-type 1 Zinc finger region, all identified Ikaros proteins contain six C2H2-type 1 Zinc finger regions. We found human Ikaros gene showed a predominant expression in the liver, lymph node, thymus, intestine, lung, mammary gland, bone marrow, brain, heart, placenta and prostate. Moreover, four available SNPs disrupted an existing exonic splicing enhancer were identified in Ikaros. Besides the reported acute lymphoblastic leukemia (ALL), the expression of Ikaros was related to the prognosis of 13 cases of cancers including blood cancers, breast, lung, ovarian and skin cancer. Moreover, the relationship between the expression of Ikaros and prognosis varied in different cancers, even in the same cancer from different database. Two tumor-related transcriptional factor (c-Fos and Elk-1) binding sites were identified within the 1.5-kb regions upstream of the transcriptional start site of human Ikaros, which may be involved in the effect of Ikaros in tumors.
Introduction
The Ikaros (IKZF1, Lyf-1) is a member of the Kruppel family of zinc finger DNA-binding proteins 1 (1) . The Ikaros protein contains two separate regions of zinc-finger domains: 4 DNA-binding zinc fingers near the N-terminus and 2 zinc fingers for protein-protein interactions near the C-terminus. The human Ikaros gene, located at 7p12, contains seven exons and gives rise to at least eight isoforms by alternative splicing (2) . All isoforms share a common C-terminal domain that contains a transcriptional activation domain and two zinc finger motifs required for hetero-or homodimerization and for interactions with other proteins, but these isoforms differ in the number of N-terminal zinc finger motifs. Long isoforms (Ik1 to 3) have at least three zinc fingers which are capable of binding DNA and considered to be functional. Short isoforms (Ik4 to 8) lack two or more zinc-finger domains, so they cannot bind DNA and impair the function of Ikaros proteins in a dominant-negative manner (3) (4) (5) (6) .
Ikaros is a transcription factor, which plays an important role in controlling hematopoietic, particularly lymphoid cell differentiation, proliferation and function by binding upstream regulatory regions of target genes and aiding in their recruitment to pericentromeric heterochromatin (PC-HC) (7) . This process leads to either activation or repression of transcription of these target genes by elaborate splicing regulation of Ikaros transcripts (3) (4) (5) (6) . Accordingly, abnormalities in splicing regulation of Ikaros would lead to significant pathological manifestations (3, 4, 8, 9) . Mice that are heterozygous for a germline mutation that results in a loss of critical DNA-binding zinc fingers of Ikaros develop a very aggressive form of lymphoblastic leukemia, suggesting that Ikaros has an important tumor suppressor function (10, 11) . Approximately 30% of pediatric B-cell acute lymphoblastic leukemia (ALL) cases showed genetic inactivation of Ikaros due to deletion or mutations (12) (13) (14) . High-level expression of dominant-negative isoforms of Ikaros with abnormal subcellular compartmentalization patterns were also found in T-cell ALL (15) and pituitary tumors (16) . However, whether Ikaros is involved in other tumors formations, especially solid tumors, is still unknown.
In the present study, we identified Ikaros genes from human, chimpanzee, macaque, orangutan, dog, cow, horse, mouse, rat, opossum, chicken, Xenopus tropicalis, zebrafish, Comparative proteomic analyses of Ikaros proteins. The amino acid sequences of Ikaros were deduced from the identified Ikaros genes and aligned using Clustal X 1.8 software (29) . The phylogenetic tree of Ikaros was obtained by using ML (maximum likelihood) (PHYML v2.4.4) (30 and NJ (neighbor-joining) (MEGA 3.0) (31) methods, and the reliability of the tree was evaluated by the bootstrap method with 1,000 replications. The program Codeml implemented in the PAML 3.14 b software package was used to investigate whether Ikaros proteins are under positive selection (32) . Six models of codon substitution, M0 (one-ratio), M1a (NearlyNeutral), M2a (PositiveSelection), M3 (discrete), M7 (ß), and M8 (ß and ˆ) were used in the analysis (33) .
Functional relevant SNP evaluation of human Ikaros gene.
Functional relevant SNPs (single nucleotide polymorphisms) of human Ikaros gene were identified as previously described (34, 35) . The SNPs were extracted from Ensembl (http:// www.ensembl.org) and NCBI's SNPdb (http://www.ncbi. nlm.nih.gov). The SNPs that could disrupt ESE/ESS (exonic splicing enhancer/exonic splicing silencer) motifs and cause missense mutation were also identified.
In silico expression analyses of human Ikaros gene.
Expressed sequence tags (ESTs) derived from human Ikaros were searched for using the BLAST programs as previously described (15) (16) (17) (18) (19) . Human Ikaros gene (NM_006060) was used as query sequences for the BLAST programs. The expression profiles for normal human tissues were obtained from GeneAnnot (36) and ArrayExpress (37) . Northern analysis of NCBI's uniGene dataset was also extracted (34, 35) .
Meta-analysis of the prognostic value of Ikaros gene in cancer.
A database named 'PrognoScan' has been developed (36) . This is: i) a large collection of publicly available cancer microarray datasets with clinical annotation, as well as ii) a tool for assessing the biological relationship between gene expression and prognosis. PrognoScan employs the minimum P-value approach for grouping patients for survival analysis, and it provides a powerful platform for evaluating potential tumor markers and therapeutic targets and is publicly accessible at http://gibk21.bse.kyutech.ac.jp/PrognoScan/ index.html. Human Ikaros (IKZF1) gene was inputted as queries and the data were collected for analysis.
Results

Comparative proteomics of Ikaros proteins identified in vertebrate genomes.
Ikaros genes were identified in the genome sequences of human, chimpanzee, macaque, orangutan, dog, cow, horse, mouse, rat, opossum, chicken, Xenopus tropicalis, zebrafish and fugu. Their amino acid sequences are shown in alignment format in Fig. 1 . Except rat and Xenopus tropicalis Ikaros proteins, which lack the first C2H2-type 1 Zinc finger region, all identified Ikaros proteins containing six C2H2-type 1 Zinc finger regions (Fig. 1) . Refined phylogenetic trees using the identified Ikaros amino acid sequences by ML and NJ methods were almost the same (Fig. 2) . It seemed that primate Ikaros proteins clustered into one group, different from other Ikaros proteins. We were unable to identify any site under positive selection with any of the six models in Ikaros proteins. Instead, the Ikaros proteins were under purifying selection (data not shown).
Expression profile of human Ikaros gene. By EST sequence search, human Ikaros gene was expressed in parathyroid, liver, lymph node, stomach, uterus, vascular, thymus, muscle, pharynx, intestine, ovary, thyroid, lung, mammary gland, blood, bone, bone marrow, brain, spleen, heart, placenta, tonsil, prostate, and connective tissue. The investigation of available microarray experiments and 'virtual northern blot' showed a predominant expression of Ikaros in the liver, lymph node, thymus, intestine, lung, mammary gland, bone marrow, brain, heart, placenta, and prostate tissue. When searched in PrognoScan database, human Ikaros was also found expressed in bladde, blood, breast cancer, gliomas, colorectal, head and neck, ovarian, lung and skin cancer tissues.
Comparative genomics on the human Ikaros gene. Transcription factor-binding sites within the 5'-region of Ikaros gene were identified (Fig. 3) . available SNPs were identified in human Ikaros gene. Among these, 5 SNPs were functionally relevant, including four available alleles disrupted an existing exonic splicing enhancer (rs11980379, rs11978363, rs6980115, rs11552047) and one SNP causing missense mutation (rs61731359). For rs61731359, an amino acid change from Asn to Asp in site 319 was reported. Moreover, two identical amino acid changes were also found for rs61731356 (site 391, Asn) and rs61731355 (site 333, Pro) ( Table I) .
Meta-analysis of the prognostic value of human Ikaros gene in cancer.
When given the gene, PrognoScan displays a summary in colorectal cancer 0/1, gliomas 0/3, head and neck cancer 0/1, lung cancer 2/10, ovarian cancer 1/2, skin cancer 1/1) with 5% significance level (Table II) . Among the four blood cancers, we found a higher expression of Ikaros associated with poor survival in the case of diffuse large B-cell lymphoma (DLBCL) and multiple myeloma. However, a lower expression of Ikaros was related to poor survival in the case of diffuse large acute myeloid leukemia (AML) and Table I . Functional relevant SNP evaluation of the human Ikaros gene.
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Fourteen tests showed an association between microarray expression in Ikaros and cancer prognosis (blood cancer 4/9, breast cancer 6/16, lung cancer 2/10, ovarian cancer 1/2, skin cancer 1/1) with 5% significance level. AML, acute myelocytic leukemia; DLBCL, diffuse large B-cell lymphoma; 1 represents poorer expression of Ikaros associated with poor survival; 2 represents higher expression of Ikaros associated with poor survival.
Among the six breast cancers, the higher expression of Ikaros was related to poor survival was found in only one case (E-TABM-158). Among the lung cases, we found a higher expression of Ikaros associated with poor survival in the case of adenocarcinoma and a lower expression of Ikaros associated with poor survival in the case of squamous cell carcinoma. Moreover, a higher expression of Ikaros associated with poor survival was found in the case of ovarian cancer, and a lower expression of Ikaros associated with poor survival in the case of skin cancer.
Discussion
Ikaros is a member of the Kruppel family of zinc finger DNA-binding proteins, which locates at 7p12 in human genome. In the present study, we identified other Ikaros genes from other 13 vertebrate genomes and found Ikaros existed in all kinds of vertebrate including fish, amphibians, birds and mammals. Moreover, except rat and Xenopus tropicalis Ikaros proteins, which lack the first C2H2-type 1 Zinc finger region, all identified Ikaros proteins containing six C2H2-type 1 Zinc finger regions (Fig. 1) . The phylogenetic tree shows that Ikaros is separated with the order fish, amphibians, birds and mammals, and primate Ikaros are almost the same and clustered together. From the alignment and phylogenetic tree, mammalian Ikaros are conversed among vertebrate genomes, suggesting that the function of Ikaros is essential for all the vertebrates in the long evolution process. Moreover, this process was under purifying selection.
Though Ikaros expression is essential for normal hematopoiesis in the lymphoid, myeloid, and erythroid lineages, it is not limited to the hematopoietic system. We found human Ikaros gene was expressed in many tissues and organs. It shows a predominant expression in the liver, lymph node, thymus, intestine, lung, mammary gland, bone marrow, brain, heart, placenta, and prostate. It implied Ikaros may be involved in the physiological functions of these tissues. Alternative splicing of Ikaros gene results in a number of mRNA and protein isoforms (Ik1-8) with distinct activity and capability of DNA binding regulating the role in controlling hematopoietic, particularly lymphoid cell differentiation, proliferation and function (3) (4) (5) (6) . Abnormalities in splicing regulation of Ikaros would lead to significant pathological manifestations (3, 4, 8, 9) . We identified four available SNPs disrupting an existing exonic splicing enhancer, which may affect the alternative splicing of Ikaros. The effects of these SNPs on Ikaros physiological and pathological function need further investigation.
Ikaros is involved in apoptosis and cell cycle regulation in lymphocytes and thought as a hematological and pituitary tumor suppressor (15, 16) . In the present study, we found Ikaros was widely expressed in solid tumors including bladder, blood, breast, colorectal cancer, gliomas, head and neck, lung, ovarian and skin cancer. Prognostic analysis of Ikaros has been reported only in AML (15) . We also found a lower expression of Ikaros was related to poor survival in AML, this was confirmed by PrognoScan analysis. However, the PrognoScan analysis depicted statistical significance in other 13 tests (blood cancer 3/9, breast cancer 6/16, lung cancer 2/10, ovarian cancer 1/2, skin cancer 1/1), which were not previously reported. It suggested that the expression of Ikaros was related to the prognosis of many cancers including hematological and solid cancers. The mechanism of Ikaros involved in the process of these tumors needed further investigation. It is important to note that relationship between the expression of Ikaros and prognosis varied in different cancers, even in the same cancer from different database. It implied that the function of Ikaros in these tumors may be multidimensional (Table II) , not just as a tumor suppressor. The c-Fos, Elk-1, GATA-1 and NKX6-B binding sites were identified within the upstream of the transcriptional start site of human Ikaros gene. c-Fos is a cellular proto-oncogene belonging to the immediate early gene family of transcription factors. Members of the Fos family dimerise with C-Jun to form the AP-1 transcription factor, which has been implicated in transformation and progression of many cancers (39) . ELK1, is a member of the Ets family of transcription factors, originally identified as a key regulator of immediate-early genes, such as FOS, which are rapidly and transiently induced following exposure to extracellular ligands that activate the MAP kinase pathways. ELK1 is also an oncogene implicated in transformation and progression of many cancers (40, 41) . These two tumorrelated transcriptional factors (c-Fos and Elk-1) may be involved in the effect of Ikaros in tumors.
